[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atypical-parkinsonism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atypical-parkinsonism":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,88,123,155,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100642000","prospective-multicenter-registry-study-of-multiple-system-atrophy-in-china-100642000",false,"NCT07644013","Prospective Multicenter Registry Study of Multiple System Atrophy in China","Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China","MSA Registry S","Inclusion Criteria\n\n1. Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or\n2. Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or\n3. Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.\n4. Age between 40 and 75 years.\n5. Ability to provide informed consent or availability of a legally authorized representative when applicable.\n\nExclusion Criteria\n\n1. Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.\n2. Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.\n3. Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.\n4. Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.\n5. Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.\n6. Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.",true,"ALL","40 Years","75 Years",{"count":22,"type":23},214,"ESTIMATED","6 Months","OBSERVATIONAL","Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited.\n\nThis prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.",[28,29,30],"Multiple System Atrophy","Parkinson's Disease","Atypical Parkinsonism",[32,33,34,35,36,37,38,39],"Multiple system atrophy","natural history","prospective cohort","multicenter registry","disease progression","neuroimaging","biomarkers","alpha-synuclein","RECRUITING","2026-06-08",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":44},"2025-06-01",{"date":48,"type":23},"2030-06-30",{"name":50,"class":51},"Peking University First Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100640300","early-molecular-biomarkers-for-differentiating-parkinsonian-syndromes-100640300","NCT07604883","Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes","Identification of Molecular Biomarkers, Including microRNAs and Metabolites, Enabling Early Differentiation of Parkinson's Disease and Atypical Parkinsonian Syndromes in a Prospective Observational Study.","BIOMARK-PS","Inclusion Criteria:\n\nPatients with suspected neurodegenerative parkinsonism in the course of PD or APS, defined according to the 2015 MDS criteria as bradykinesia accompanied by at least one additional symptom: rigidity and\u002For resting tremor.\n\nAge between 40 and 80 years. Written informed consent for participation in the study. Duration of parkinsonian symptoms shorter than 3 years. Abnormal dopamine transporter single-photon emission computed tomography (DaTscan) result confirming presynaptic dopaminergic neuronal degeneration.\n\nExclusion Criteria Lack of consent to participate in the study. Secondary or drug-induced parkinsonism. Other central nervous system (CNS) disorders (e.g., neoplastic or vascular processes) that could account for the symptoms.\n\nActive malignancy, infection, or autoimmune inflammatory disease. Severe systemic diseases, including advanced heart failure (New York Heart Association \\[NYHA\\] class III-IV), poorly controlled diabetes mellitus, renal failure with glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin\u002F1.73 m², or hepatic failure.\n\nPresence of a known monogenic mutation causing parkinsonism according to the Online Mendelian Inheritance in Man (OMIM) classification.\n\nAntibiotic therapy or use of probiotics within 3 months prior to the study visit.\n\nPregnancy or breastfeeding.","80 Years",{"count":63,"type":23},200,"This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian syndromes (APS). The study will enroll up to 100 patients with PD, 50 patients with suspected APS, and 50 healthy controls.\n\nParticipants will undergo clinical assessments and provide blood, urine, and stool samples at baseline and after 12-18 months of follow-up. Molecular analyses, including microRNA profiling, metabolomics, RNA sequencing (RNA-seq), and microbiome analysis, will be performed to identify disease-specific diagnostic signatures.\n\nThe primary objective is to detect differences in molecular profiles among patients with PD, patients with APS, and healthy controls. Secondary objectives include evaluating the diagnostic accuracy of biomarker panels and assessing longitudinal changes in these biomarkers over time.\n\nAlthough participants will not receive direct therapeutic benefits, the study may contribute to the development of non-invasive tools for the early diagnosis and improved differentiation of parkinsonian disorders.",[66,30,28,67,68],"PARKINSON DISEASE (Disorder)","Progressive Supranuclear Palsy (PSP)","Dementia With Lewy Bodies (DLB)",[70,71,72,73,74,75],"parkinson disease","atypical parkinsonism","progressive supranuclear palsy","multiple system atrophy","dementia with lewy bodies","biomarker","NOT_YET_RECRUITING","2026-05-25",{"date":79,"type":44},"2026-05-28",{"date":81,"type":23},"2026-06-04",{"date":83,"type":23},"2029-06-04",{"name":85,"class":86},"International Institute of Molecular and Cell Biology in Warsaw","OTHER_GOV",2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":52},"100640930","speech-amplification-devices-for-parkinson-disease-talker--and-technology-driven-enhancements-100640930","NCT07599696","Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements","Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements","Inclusion Criteria:\n\n* Dominant speakers of North American English\n* Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP\u002FMSA\u002FPSP)\n* Present with changes in their speech\u002Fvoice\n\nExclusion Criteria:\n\n* History of any other speech, language, or neurological concern other than Parkinson\u002Fparkinsonism.\n* Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and\u002For use of a cochlear implant.","50 Years",{"count":97,"type":23},100,"INTERVENTIONAL",[100],"NA","The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.",[103,30],"Parkinson Disease",[105,106,71,107,108,109,110,111,112,113],"speech","Parkinson's disease","speech acoustics","speech-language pathology","hypophonia","voice","voice disorders","speech disorders","dysarthria","2026-05-14",{"date":116,"type":44},"2026-05-20",{"date":118,"type":44},"2024-03-01",{"date":120,"type":23},"2028-05-31",{"name":122,"class":51},"Michigan State University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":131,"targetDuration":4,"studyType":98,"phases":133,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100582049","phase-1-standard-optimization-of-stem-cells-in-parkinsons-disease-and-atypical-parkinsonism-100582049","NCT06858254","Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism","Standard Optimization of Autologous Stem Cells by Intranasal and Intravenous Administration to Treat Parkinson's Disease and Atypical Parkinsonism","SO-ASC-INIVAT","General Inclusion Criteria:\n\n* Participants aged 40-75 years old with a diagnosis of PD or PPS (DLB, PSP, MSA, CBD with parkinsonism) based upon clinical criteria and standardized testing\n* Participants time of documented PD or PPS is \\\u003C\u002F= 6 years\n* Participants with an anticipated survival of at least 3 years in the investigator's opinion\n* Participants who are willing and able to give informed consent\n* Participants who can comply with the study protocol over the 18-month duration\n* Stable medical profile for 60 days prior to the initial intake screening\n* Participants can ambulate at least 25m without assistance\n* No known history of heparin-induced thrombocytopenia\n\nPD Inclusion Criteria:\n\n* Idiopathic Parkinson's disease patients who meet the MDS's Clinical Diagnostic Criteria for Parkinson's disease\n* Responsive to levodopa or dopamine agonists defined by \\>\u002F= 33% improvement in \"Off\"\u002F\"On\" symptoms by MDS-UPDRS-III\n* A modified Hoehn and Yahr stage of \\\u003C\u002F= 3\n* Neuroimaging findings are consistent with PD and absent of atrophy or other brain pathology inconsistent with PD\n* \"Normal\" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value \\>\u002F= 26\n\nPPS Inclusion Criteria:\n\nDLB -\n\n* High probability of cognitive capacity to give informed consent by the Montreal Cognitive Assessment (MoCA), with a value \\>\u002F= 23\n* Probable DLB - DLB consortium: Two or more core clinical features are present (including features of parkinsonism for the study), or only one core clinical feature is present, but with one or more indicative biomarkers\n* Core clinical features:\n\n  * Fluctuating cognition with pronounced variations in attention and alertness\n  * Recurrent visual hallucinations that are typically well-formed and detailed Rapid eye movement (REM) sleep behavior disorder (RBD), which may precede cognitive decline\n* One or more spontaneous cardinal features of parkinsonism: bradykinesia, resting tremor, or rigidity\n* Indicative biomarkers:\n\n  * Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT\u002FPET\n  * Abnormal (low uptake) I-MIBG myocardial scintigraphy\n  * Polysomnographic confirmation of REM sleep without atonia\n\nPSP -\n\n* MDS Diagnostic Criteria for probable PSP with predominant parkinsonism (PSP-P)\n* Ocular motor dysfunction: vertical supranuclear gaze palsy or slow velocity of vertical saccades or frequent macro square wave jerks (\"eyelid-opening apraxia\")\n* Ocular motor dysfunction + akinetic-rigid, axial predominant, levodopa resistant or with tremor and\u002For asymmetric and\u002For levodopa responsive (akinesia)\n* \"Normal\" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value \\>\u002F= 26\n\nMSA -\n\n* MDS Diagnostic Criteria for clinically probable MSA\n* Autonomic dysfunction\n* Parkinsonism\n* Cerebellar syndrome, including at least one of gait ataxia, limb ataxia, cerebellar dysarthria, or oculomotor features\n* \"Normal\" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value \\>\u002F= 26\n\nCBD -\n\n* Chronic progressive course\n* Asymmetric onset\n* Higher cortical dysfunction: apraxia, speech apraxia, non-fluent aphasia, alien limb phenomena, or cortical sensory loss\n* Movement disorder: rigid\u002Fakinetic syndrome and either dystonic limb posturing or focal myoclonus in limb, and levodopa resistant\n* \"Normal\" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value \\>\u002F= 26\n\nExclusion Criteria:\n\n* Other non-PD\u002FPPS Parkinsonism (e.g., drug-induced, vascular parkinsonism)\n* No strong familial history of PD\u002FPPS not attributable to environmental exposure or any known genetic predisposition to PD\u002FPPS\n* Unable to receive\u002Ftolerate neuroimaging (e.g., MRI-incompatible cardiac pacemaker)\n* Unable to maintain\u002Ftolerate supine position with cervical neck extension\n* Active systemic infection or local infection near the lumbar pelvis region\n* Any bone marrow aspiration from the pelvis within 6 months of initial screening\n* Any musculoskeletal-pelvis contraindications to BMA harvest from the PSIS\n* Concurrent enrollment in another PD\u002FPPS study or having taken\u002Freceived another investigational intervention within 6 weeks of initial screening\n* Malignancy diagnosed \\\u003C\u002F= 2 years prior to initial screening\n* History of intracranial or nasopharyngeal surgery deemed detrimental to the participant during the trial, including brain surgery\u002Fstereotactic procedure for PD\u002FPPS\n* History of electroconvulsive therapy\n* Chronic Kidney Disorder (CKD) \\> Stage II or eGFR \\\u003C60 mL\u002Fmin\n* Autoimmune disease, including:\n\n  * Rheumatoid Arthritis (RA)\n  * Systemic Lupus Erythematosus (SLE)\n* Any disorders of glucocorticoid excess or diseases requiring systemic steroids or immune-modulating therapies\n* Cardiac disease deemed significant:\n\n  * Poorly controlled hypertension (BP \\>\u002F=140\u002F90)\n  * NYHA class III or IV congestive heart failure\n  * History of a significant ventricular arrhythmia\n* Obesity class II or higher (BMI \\>\u002F= 35)\n* Moderate-to-uncontrolled diabetes HbA1c \\>\u002F= 7%\n* Osteoporosis\n* A history of other severe systemic disorders, including significant CVA, TBI, seizure, encephalitis, meningitis, or psychiatric disorder that is deemed potentially harmful to the participant by the PI\n* Positive for HIV, HBV, HCV, or syphilis\n* Any of the following lab abnormalities:\n\n  * Hematology: Hgb \\\u003C 10 g\u002Fdl, ANC \\\u003C 1.550\u002FL, platelets \\\u003C 100,000 \u002FL \\>Chemistry: albumin \\\u003C 3.0 g\u002FdL, serum creatine \\> 1.5 x ULN, total bilirubin \\> 1.5 x ULN, AST\u002FALT\u002FALP \\> 2.0 x ULN\n* Female or another gender with childbearing potential not willing to adopt barrier method(s) of contraception, plus one other form, including:\n\n  * Intrauterine system (IUS)\n  * Intrauterine device (IUD)\n  * Oral, injected, or implanted hormonal contraception\n* Female or another gender who is lactating\u002Fbreastfeeding or has a positive urine or serum pregnancy test at intake screening\n* Any disorder that compromises the participant's ability to give appropriate informed consent or hinders the ability to perform the assessment and receive the study's interventions\n* Any other condition not listed above that is deemed potentially harmful to the participant by the PI",{"count":132,"type":23},60,[134,135],"PHASE1","PHASE2","The purpose of this study is to measure outcomes using intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients.",[30,138],"Parkinson Disease (PD)",[30,140,141,142,143,144,145],"Parkinson-Plus Syndrome","Stem Cells","MSCs","Epigenetics","Metagenomics","Parkinson's Disease","2025-02-27",{"date":148,"type":44},"2025-03-05",{"date":150,"type":23},"2025-04-01",{"date":152,"type":23},"2028-04",{"name":154,"class":51},"Apeiron Research Center",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":17,"sex":18,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":165,"conditions":166,"keywords":171,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":52},"100556734","proteinopathies-expression-in-skin-of-neurodegenerative-disorders-100556734","NCT06528964","Proteinopathies Expression in Skin of Neurodegenerative Disorders","Expression of Proteinopathies in Skin Biopsies of Patients With Neurodegenerative Disorders","Inclusion Criteria for patients:\n\n* Patients 45 years and older\n* Men and women\n* Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus\n* Patients that voluntarily accept to participate in the study and accept the consent form\n\nInclusion Criteria healthy control subjects:\n\n* People 45 years and older\n* Men and women\n* Subjects can be related to a patient but not by blood (for example spouse of a patient)\n* Subjects don't have direct family history of a neurodegenerative control\n* Subjects don't have any clinical findings suggesting dementia\n* Subjects voluntarily accept to participate in the study and accept the consent form\n\nExclusion Criteria:\n\n* Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia\n* Patients in which the diagnosis is not clear or hasn't been confirmed\n* Patients or controls that have a neuroinfection\n* Patients or controls that a diagnosed skin disease\n* Patients that have an \"atypical\" presentation of the disease\n* Patients or controls that have diagnosis of a coagulopathy","45 Years",{"count":164,"type":23},40,"The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \\[TDP43\\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is:\n\n* Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects?\n\nSkin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.",[167,168,103,30,169,170],"Alzheimer Disease","Frontotemporal Dementia","Amyotrophic Lateral Sclerosis","Normal Pressure Hydrocephalus",[172,173,174,175],"Alpha Synuclein Pathology","Tauopathies","TDP-43 Proteinopathies","Beta-Amyloid","2024-12-13",{"date":178,"type":44},"2024-12-16",{"date":180,"type":44},"2023-12-20",{"date":182,"type":23},"2026-11-01",{"name":184,"class":51},"Universidad Autonoma de San Luis Potosí",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":18,"minAge":193,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":196,"conditions":197,"keywords":209,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":52},"100561944","neurodegenerative-diseases-progression-markers-markers-ndd-100561944","NCT06596746","Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study","MARKERS-NDD","Inclusion Criteria:\n\n* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders\n\n  * Patients with diagnosis of Parkinson's Disease\n\n    * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank\n  * Diagnosis of Movement Disorder not related to Parkinson's Disease\n\n    * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;\n    * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;\n    * Diagnosis of Essential Tremor\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n* Patients affected by cognitive impairment (CI) and dementia\n\n  * Diagnosis of probable:\n\n    * Lewy Body Dementia\n    * Alzheimer's Disease\n    * Mild Cognitive Decline\n    * Subjective memory complaints\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.","10 Years",{"count":195,"type":23},600,"MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.",[198,103,199,200,28,173,167,201,202,30,174,169,203,204,205,206,207,208],"Neurodegenerative Diseases","Synucleinopathies","Lewy Body Disease","Corticobasal Degeneration","Supranuclear Palsy, Progressive","Frontotemporal Lobar Degeneration","Movement Disorders","Cognitive Impairment","Dementia","Iron Overload","Neurodegeneration With Brain Iron Accumulation (NBIA)",[198,210,211,212,213,214,215,216,217,218,219,220,221,222,223],"Markers","Gait analysis","Wearable inertial sensors","IMU","Artificial intelligence","AI-Video gait analysis","Handwriting analysis","Voice-based artificial intelligence systems","imaging","multimodal analysis","electroencephalogram","cortical activity","gut microbiota","laboratory blood chemistry parameters","2024-09-11",{"date":226,"type":44},"2024-09-19",{"date":228,"type":23},"2024-09-09",{"date":230,"type":23},"2034-09-09",{"name":232,"class":233},"Casa di Cura San Raffaele Cassino","NETWORK"]